New study tracks Dupilumab's Real-World impact on swallowing and quality of life

NCT ID NCT06695897

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 150 adults with eosinophilic esophagitis (EoE) who are starting dupilumab as part of their normal care. Researchers will collect information on medical history, symptoms, and quality of life over two years to see how well the treatment works in real-world settings. The goal is to better understand long-term safety and effectiveness outside of a controlled clinical trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site Number: 0000001

    RECRUITING

    Dachau, Bavaria, 85221, Germany